Founded in March 2006 as a spin-off from Dr. Mestres’ Systems Pharmacology lab under the auspices of the IMIM, Chemotargets offers validated and cutting-edge computational methodologies with top market predictive performance.
The innovation strategy is driven by new cutting edge methods generated at Dr. Mestres’ lab at IMIM, a leading academic center of excellence based in Barcelona. Dr. Mestres is the author of more than 150 peer-reviewed publications.
Chemotargets is currently recognized as a global leader in predictive analytics solutions for pharmaceutical and biotechnology companies and research institutions.
Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and improving cost-efficiency.
Prous Institute for Biomedical Research’s recent strategic investment in Chemotargets will allow product development to be accelerated and new capabilities to be acquired in order to support the company’s vision.